'Pyxis profit-taking after yesterday's 160% surge on positive Phase 2 data trigger premarket drop'

 

The stock experienced a sharp 31.14% decline in premarket trading on December 18, 2025, following a massive rally the previous day driven by encouraging preliminary results from a Phase 2 trial of NGC-Cap, a next-generation cancer therapy. The data showed increased exposure to cancer-killing metabolites with comparable safety to standard treatments in breast cancer patients, sparking high retail interest and volume exceeding 39 million shares. However, as is common in volatile biotech penny stocks post-news, traders locked in gains amid fading momentum, amplified by the recent 1-for-25 reverse stock split that heightened share scarcity and price swings. No new negative developments emerged, but the pullback reflects typical digestion of the prior catalyst in a low-float environment.

https://finviz.com/quote.ashx?t=PCSA&p=d